Publication | Closed Access

Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

Neopetra StudyBreast OncologyOncologyDual Her2 BlockadeReal-world EffectivenessPharmacologyBreast CancerPharmacotherapyCancer TreatmentMedicine